血脂康对心肌梗死患者的疗效及安全性研究  

Efficacy and safety of Xuezhikang treatment for patients with myocardial infarction

作　　者：高明明[1] 刘云芝[1] 杨新春[1] 

机构地区：[1]首都医科大学附属北京朝阳医院心脏中心,北京100020

出　　处：《中国心血管杂志》2007年第3期182-184,共3页Chinese Journal of Cardiovascular Medicine

基　　金：国家"九五"科技攻关项目(96-906-02-10)

摘　　要：目的研究血脂康对冠心病心肌梗死患者调整血脂的作用以及是否能降低冠心病相关事件和死亡。方法入选204例确诊为心肌梗死的患者,其血清总胆固醇水平在4.40～6.47 mmol/L(170～250 mg/dl)。采取双盲与安慰剂对照方法,定期检测血脂及其他相关指标,并收集记录所有发生事件及不良反应,平均随访4年。结果血脂康治疗组总胆固醇(TC)水平和低密度脂蛋白胆固醇(LDI-C)水平分别下降13.2%和19.5%,与安慰剂组相比差异有统计学意义;血脂康治疗组主要终点和次要终点事件发生率、冠心病死亡及总死亡数目均有所减少。临床不良反应和实验室指标异常两组间差异无统计学意义。结论血脂康对心肌梗死患者具可靠调脂作用,可使冠心病事件及死亡减少。并具有良好的安全性及耐受性。Objective To evaluate the efficacy and safety of therapy with Xuezhikang for regulating lipid and to investigate whether Xuezhikang treatment can reduce the cardiac events and mortality in myocardial infarction patients. Methods A total of 204 patients （with definite myocardial infarction history, aged 18-75 years, serum cholesterol level 4. 40-6.47 retool/L） were randomly assigned to two groups： receiving 1.2g Xuezhikang （n= 102, Xuezhikang group） or placebo （n= 102, control group）. The mean follow-up period was 3.9 2.1 years. The primary end-points were nonfatal myocardial infarction or cardiac deaths. Results Serum TC and LDL-C were reduced by 13.2% and 19.5% respectively （P〈0. 0001）. The incidence of the nonfatal myocardial infarction was 3.9% in Xuezhikang group and 9.8% in control group （P=0. 0966） ; the incidences of cardiac deaths and the total mortality were lower in Xuezhikang group than in control group. Xuezhikang therapy was well tolerated with no increase in adverse events. Conclusions Compared with placebo, Xuezhikang can significantly reduce serum LDL- C and TC levels; can decrease the incidence of cardiac events. It is generally safe and well tolerated.

关 键 词：冠状动脉疾病 血脂康 他汀类药 血脂 

分 类 号：R542.22[医药卫生—心血管疾病] R972.6[医药卫生—内科学]